ABEO Abeona Therapeutics Inc

$ABEO I’m invested in Abeona for years now, lot of downs more than ups. BUT I really recommend you searching for Hayden Zevaskyn treatment on Facebook, not only that this brave little boy got treated a few weeks ago at UTMB as first patient successfully, he will probably count in Q3. I assume we see 8 patients treated and 7 revenue in Q3, the more quarters will pass the more Abeona will grow. This therapy is unique and so life changing. If you are crazy and short, have the courage and watch what you are betting against. We have Zevaskyn, enough cash ~140 million in the bank and future milestones from UX111 + the pipeline. I’m more bullish than ever and love to see the progress. If not this management scale it right than there will be one who can for sure ;-) Not speculating for an BO at the moment but with decreasing MC more likely. PS: If you watched Haydens story and progress, sent him some money rather then buying BS or shorts

$ABEO we’re close the the March low while the company is currently in a much better position than 7 months ago. Buying opportunity here before the next earnings report in Nov.

$ABEO When a highly shorted stock receives great news, it often triggers a short squeeze, causing the stock price to spike rapidly.🚀 What Happens Step-by-StepThe Catalyst: Great news or positive earnings break.Initial Buying: New buyers jump in, pushing the stock price up.Margin Pressure: Short sellers face losses as the price climbs, risking margin calls from brokers.The Squeeze: Shorts rush to buy back shares to close out their positions.Price Spiral: That forced buying adds massive extra demand, driving the price even higher in a feedback loop. With ABEO, the question is probably not IF, but WHEN. Which shorts are going to be left holding the bag?

$ABEO - Wooooo! roller coasting prices.... its going to be crazy soon enough! Remember these few things, Multiple treatment centers, only first year in commercial with a life saving product that no one else has.... That's the story -

$ABEO Small fundamental reminder, alone the UX111 upcoming royalties are between 10-20% from the MC at this moment.

$ABEO "Abeona Therapeutics Inc. (NASDAQ: ABEO) has a net cash position of approximately $126.95 million ($2.22 per share), based on the latest balance sheet data. Balance Sheet Breakdown • Cash & Cash Equivalents: $146.83 million • Total Debt: $19.87 million • Net Cash: $126.95 million • Net Cash Per Share: $2.22 So at the current price investors are paying net of cash $2.47 per share for the entire Zevaskyn franchise and all the other stuff. ABSOLUTELY CRAZY.

$ABEO Abeona is eligible for tiered royalties ranging from mid-single-digit percentages to 8% of net sales, along with up to $30 million in commercial milestone payments following regulatory approval...BIG

$ABEO Their valuing the company @ 100 million dollars (minus the cash on hand) with 2 approved drugs/Zevaskyn having a market potential of 4 billion incredibly cheap!!!!!! Someone is going buy them out on the cheap imo

$ABEO AI Overview Abeona Therapeutics is targeting a manufacturing capacity of 10 slots (procedures) per month by 2027. • Maximum Targeted Capacity: 10 procedures per month. The company is scaling up its manufacturing capabilities by adding a second production suite to reach this 10-slot monthly goal. • Current Operational Baseline (2026): Production is operating at 6 slots per month, with early Qualified Treatment Centers (QTCs) handling roughly 1 to 2 patients per month. • Financial Break-Even Cadence: Management has stated that the therapy achieves free-cash-flow positivity once it scales to more than 3 patients treated per month. Each authorized treatment center is expected to ultimately maintain a steady cadence of roughly 1 patient per month. NOTE: 10 procedures per month would result in total revenues in 2027 of about $360M at a Gross Margin of about $85% to 90%.

$ABEO With an eighth site identified for Zevaskyn, UX111 approved with royalties and milestone payments on the horizon and a prostate cancer drug in the pipeline, how someone does not buy this company is a bit of a mystery considering PTs that consider future earnings and the stocks current price. I have to believe longs will be rewarded as the solid science behind the company appears to portend well for the prostate cancer drug. We shall see.

$ABEO Estimated earnings and revenue for Q3 are about 50% better than Q2. So why the weakness?

$ABEO As of the most recent official FINRA bi-monthly short interest report (settlement date September 30, 2026), 16,882,889 shares of Abeona Therapeutics Inc. (ABEO) were sold short. This figure represents an increase of 1,137,791 shares (approximately +7.23%) from the prior report of 15,745,098 shares as of September 15, 2026. The corresponding short interest ratio (days to cover) is 11.57. The most compelling setup would be high short interest (16.88M shrs or 33.30% of the float) + elevated days to cover (11.57 days) + a positive catalyst (more treatments and realized revenue) + rising share price and volume. Waiting...

$ABEO They try so hard 😂 I know watching the charts everyday makes you go nuts but the games played with Abeona are really insane. Short interest published today will be interesting

$ABEO They want your shares folks. They'll eventually try to create some sort of scandal or bad news to frighten you into selling your shares....

$ABEO - Remember - New South East center - Now added more employee (NON-EXEC) shares which means GROWTH.... I have officially hit my 10k goal...now just have to wait and let the company grow! Grateful to share my journey with you all!

$ABEO - simple points to remember....What does this service provide? How many other companies can do it? Are they building a good foundation to build the services out of ? We are watching a singular source of service being built out and we were able to buy this under $4,$5, and $6..... 10K of shares is the goal.....

$ABEO If ABEO has indeed turned the corner and become profitable this is one of the the best value plays in Biotech IMO

$ABEO Q3 started with 3 Zevaskyn treatments. Muy number for this Q3 is 9 treatments done ✅

$ABEO With the profit RARE stands to make, why not just buy ABEO? I understand taking on their current commercial product is not exactly in their wheelhouse, but if run correctly can also be a moneymaker. Hell, once profitable they can sell it to someone else.

$ABEO High probability this retests $4.80 and possibly $4.72 depending on overall market conditions. But long term.... when they execute 50% - 300% + from current levels.